Nursing
Cancer Chemotherapy Pharmacology Practice Questions: Chapter 33-34 Protein Tyrosine Kinase Inhibitors of VEGFR and other tyrosine kinases: pazopanib (Votrient)
Click on the correct answer.
Pazopanib (Votrient):
First-line treatment of renal cell carcinoma (RCC).
Inhibits tyrosine kinases.
Both
Neither
Pazopanib mechanism of action: tumor growth inhibition by means of angiogenesis inhibition.
True
False
Angiogenesis inhibition of multiple kinases by pazopanib involve/involves:
Inhibition of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).
Fibroblast growth factor receptor(FGFR-1, FGFR-3)
Both
Neither
Pazopanib (Votrient)
With respect to progression free survival (PFS) and overall survival (OS), pazopanib is considered "non-inferior" compared to sunitinib.
Sunitinib administration is usually found to exhibit a better safety margin (not including hepatotoxicity risk) and better tolerability compared to pazopanib.
Both
Neither
Pazopanib,a targeted treatment, appears to have replaced toxic high-dose cytokine therapy (such as interferon-alpha) in treating RCC.
True
Falls
Soft tissue sarcoma:
Patients have been treated with anthracycline-based chemotherapy protocols.
Currently, pazopanib represents an oral, safer alternative for those who have either not responded to more toxic agents or have been unable to tolerate those more toxic agents.
Primary metabolism by the hepatic cytochrome P450 drug metabolizing system with CYP3A4 being the most prominent isoform involved.
Excretion: mainly in the feces
Both
Neither
Severe hepatotoxicity may occur with pazopanib, sunitinib, and regorafenib administration.
True
False
Pazopanib administration may, based on mechanism of action, cause fetal harm. Women of reproductive potential should utilize effective contraception both during treatment and for minimum of two weeks following the last pazopanib dose.
